Advertisement

Topics

Agilent 'outpacing the market' with double-digit biopharma growth

12:27 EDT 22 Aug 2017 | BioPharma-Reporter

Agilent Technologies says it is benefitting from increased antibody and biosimilar R&D and manufacturing, reporting a double-digit growth for its third quarter.

Original Article: Agilent 'outpacing the market' with double-digit biopharma growth

NEXT ARTICLE

More From BioPortfolio on "Agilent 'outpacing the market' with double-digit biopharma growth"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...